Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Next Previous
Trial Profile

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir/ritonavir (Primary) ; Bedaquiline (Primary) ; Bictegravir (Primary) ; Cabotegravir (Primary) ; Clofazimine (Primary) ; Cobicistat (Primary) ; Darunavir/ritonavir (Primary) ; Delamanid (Primary) ; Dolutegravir (Primary) ; Doravirine (Primary) ; Ethambutol (Primary) ; Isoniazid (Primary) ; Levofloxacin (Primary) ; Linezolid (Primary) ; Lopinavir/ritonavir (Primary) ; Moxifloxacin (Primary) ; Pyrazinamide (Primary) ; Rifabutin (Primary) ; Rifampicin (Primary) ; Ritonavir (Primary) ; Tenofovir alafenamide (Primary)
  • Indications HIV infections; HIV-1 infections; Tuberculosis
  • Focus Pharmacokinetics

    • Most Recent Events

    • 26 Jan 2024 Planned End Date changed from 15 Oct 2025 to 11 Mar 2026.
    • 26 Jan 2024 Planned primary completion date changed from 15 Oct 2025 to 11 Mar 2026.
    • 28 Jun 2021 Status changed from not yet recruiting to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top